{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:43Z","timestamp":1786991623323,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001279","name":"Great Ormond Street Hospital Charity","doi-asserted-by":"publisher","award":["VS0622"],"award-info":[{"award-number":["VS0622"]}],"id":[{"id":"10.13039\/501100001279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T03:43:51Z","timestamp":1712979831000},"page":"554-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7137-9982","authenticated-orcid":false,"given":"Ilaria","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-2424","authenticated-orcid":false,"given":"Rossa","family":"Brugha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-2861","authenticated-orcid":false,"given":"Henkjan J","family":"Verkade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.04.006_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.04.006_bib0002","unstructured":"The clinical and functional TRanslation of CFTR (CFTR2); available at http:\/\/cftr2.org. Date last updated: April 7, 2023. Date last accessed: 31 August 2023."},{"key":"10.1016\/j.jcf.2024.04.006_bib0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jcf.2024.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.04.006_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.04.006_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.04.006_bib0007","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","volume":"26","author":"Sellers","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2024.04.006_bib0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MPG.0000000000003944","article-title":"Towards a standardized classification of the hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN\/NASPGHAN position paper","volume":"78","author":"Bodewes","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.04.006_bib0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jcf.2023.01.012","article-title":"Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators","volume":"22","author":"Colombo","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"23","key":"10.1016\/j.jcf.2024.04.006_bib0010","first-page":"00087","article-title":"Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"S1526-0542","author":"Eldredge","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2024.04.006_bib0011","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ppul.25779","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: a case series","volume":"57","author":"Ragan","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.04.006_bib0012","series-title":"Annual data report","article-title":"Cystic fibrosis foundation patient registry","year":"2020"},{"key":"10.1016\/j.jcf.2024.04.006_bib0013","series-title":"ECFSPR annual report 2021","author":"Zolin","year":"2023"},{"key":"10.1016\/j.jcf.2024.04.006_bib0014","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf July 14, 2023 update."},{"key":"10.1016\/j.jcf.2024.04.006_bib0015","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217660s000lbl.pdf."},{"key":"10.1016\/j.jcf.2024.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jcf.2023.06.013","article-title":"Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Terlizzi","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1327958","article-title":"One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes","volume":"10","author":"Castaldo","year":"2024","journal-title":"Front Mol Biosci"},{"issue":"23","key":"10.1016\/j.jcf.2024.04.006_bib0018","first-page":"00129","article-title":"Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and liver transplant","volume":"S1569-1993","author":"Tachtatzis","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0019","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/pharmaceutics15051438","article-title":"Application of physiologically based pharmacokinetic modeling to predict drug-drug interactions between elexacaftor\/tezacaftor\/ivacaftor and tacrolimus in lung transplant recipients","volume":"15","author":"Hong","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jcf.2024.04.006_bib0020","unstructured":"https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Case_Reports2017_0.pdf."},{"key":"10.1016\/j.jcf.2024.04.006_bib0021","unstructured":"https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Case_Series2017_0.pdf."},{"issue":"1","key":"10.1016\/j.jcf.2024.04.006_bib0022","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.jcf.2021.05.008","article-title":"Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis","volume":"21","author":"Smith","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0023","doi-asserted-by":"crossref","first-page":"e01261","DOI":"10.14309\/crj.0000000000001261","article-title":"The role of cystic fibrosis transmembrane conductance regulator modulators after liver transplantation in persons with cystic fibrosis","volume":"11","author":"Maradiaga","year":"2024","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.jcf.2024.04.006_bib0024","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ppul.26217","article-title":"Outcome of elexacaftor\/tezacaftor\/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation","volume":"58","author":"\u00d8rum","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.04.006_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis","volume":"21","author":"McKinzie","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0026","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2024.04.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2024.04.006_bib0028","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.04.006_bib0029","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0031","first-page":"e41697","article-title":"The effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jcf.2024.04.006_bib0032","first-page":"6","article-title":"CFTR modulator therapy in patients with cystic fibrosis and an organ transplant","volume":"27","author":"Mitchell","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2024.04.006_bib0033","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.transproceed.2022.02.015","article-title":"Antifungal prophylaxis and treatment among lung transplant recipients in early postoperative stage: a single-center study","volume":"54","author":"Pi\u00f3ro","year":"2022","journal-title":"Transplant Proc."},{"key":"10.1016\/j.jcf.2024.04.006_bib0034","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2013a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcf.2024.04.006_bib0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.006_bib0036","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a Phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:31:37Z","timestamp":1777649497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199324000511"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.04.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}